With the pandemic and structural reforms taking their toll on the NHS workforce, Oli Hudson looks at how pharma can develop a sensitive and intelligent engagement approach that reflects the climate of change and uncertainty faced by clinical teams
Life science companies were challenged by the sudden shift in ways of working as the COVID-19 pandemic began. But in moving critical work and even some large-scale events to virtual platforms, pharmaceutical teams learned valuable lessons and embraced new technologies that will become part of their long-term strategy.
The COVID-19 pandemic has brought into question how we approach care across multiple disease areas in the future. But what does this mean in cancer? Hear from Bristol Myers Squibb’s (BMS) Executive Medical Director, Hubert Bland, who believes that in order to advance in cancer care, we must learn from the COVID-19 response and adopt a collaborative approach across the healthcare industry.